Capital One analyst Zegbeh Jallah downgraded Kodiak Sciences to Equalweight from Overweight with a $7 price target after the company reported that the GLEAM and GLIMMER studies did not meet their primary efficacy endpoints of showing non-inferior visual acuity gains for tarcocimab dosed every eight to 24 weeks after three monthly loading doses compared to aflibercept given every eight weeks after five monthly loading doses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KOD:
- Kodiak Sciences (NASDAQ:KOD) Tanks after Tarcocimab Disappoints in Phase 3 Trials
- Kodiak Sciences falls 48% to $3.73 after discontinuing development of tarcocimab
- Kodiak Sciences announces topline results from tarcocimab tedromer results
- Kodiak Sciences participates in a conference call with JPMorgan